Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Peadiatric pneumonia by Teo Yan


Published on

  • Be the first to comment

Peadiatric pneumonia by Teo Yan

  1. 1. Definition Pneumonia is an inflammation of the pulmonary parenchyma Most caused by microorganisms, noninfectious causes include aspiration of food or gastric acid, foreign bodies, hydrocarbons, and lipoid substances, hypersensitivity reactions, and drug- or radiation-induced pneumonitis
  2. 2.  classified as community-acquired, hospital- acquired, or ventilator-associated -40–80% of children with community- acquired pneumonia.-Streptococcus pneumoniae (pneumococcus) is the most common bacterial pathogen
  3. 3. Epidemiology Pneumonia is substantial cause of morbidity and mortality in childhood (particularly among children <5 yr of age) Estimated approximately 4 million deaths children among worldwide
  4. 4. Global distribution of deaths among children under age5, by cause, 2010
  5. 5. Organisms of pneumonia bacterial or viral cause of pneumonia can be identified in 40–80% of children with community-acquired pneumonia. Streptococcus pneumoniae (pneumococcus) is the most common bacterial pathogen, followed by Chlamydia pneumoniae and Mycoplasma pneumoniae
  6. 6. Leading Etiologic Agents of Pneumonia Infantsand Children S.aureus S.aureus
  7. 7. Pathophysiology Virusairbornedropletsmouth or noselungsvirus incaded cells lining airway and alveoli cell death(protective process) immune system responds  more lung damage  fluid leak into alveoli(due to WBC,lymphocytes activate)  interrupts normal transportation of oxygen
  8. 8.  Bacterial invasion triggers the immune system to send neutrophils kill the offending organisms, and also release cytokines  fever, chills, and fatigue
  9. 9. Types of pneumonia Classify by clinically: Lobar pneumonia-infection that only involves a single lobe, or section. Bronchopneumonia - affects the lungs in patches around the tubes (bronchi or bronchioles)
  10. 10. Clinical features Fever Dyspnoea Cough ( productive or non-productive ) Lethargy Poor feeding
  11. 11. Physial examination Tachypnoea,nasal flaring and chest indrawing Consolidation with dullness on percussion End –inspiratory respiratory coarse carckles over the effeted area Decreased breath sounds and bronchial breathing
  12. 12. Assessment of severity ofpneumonia The predictve value of respiratory rate for the diagnosis of pneumonia Tachypnoea is defined as follows : < 2 months age: > 60 /min 2- 12 months age: > 50 /min 12 months – 5 years age: > 40 /min
  13. 13. Assessment the severity of pneumoniaAGE < 2months AGE>2 months – 5yrs oldSevera pneumonia Mild pneumonia severe chest indrawing fast breathing or fast breathing Severe pneumoniaVery severe pneumonia chest indrawing not feeding convulsion Very severe pneumonia abnormally sleepy or difficult to not able to drinkwake convulsions fever/low body temperature drowsiness hypopnoea with slow irregular malnutritionbreathing
  14. 14. Investigations Chest X-ray White blood cell count Blood culture Pleural fluid analysis Serology Nasopharyngeal aspirate
  15. 15. Chest X-ray
  16. 16. Investigations elevated WBC count in the range of 15,000- 40,000/mm and a predominance of granulocytes erythrocyte sedimentation rate (ESR) C–reactive protein (CRP) anti-streptolysin O (ASO) titer useful in the diagnosis of group A streptococcal pneumonia
  17. 17. Viral pneumonia several days of symptoms of an upper respiratory tract infection eg: rhinitis and cough Fever, lower than in bacterial pneumonia Tachypnea intercostal, subcostal, and suprasternal retractions, nasal flaring, and use of accessory muscles cyanosis
  18. 18. Investigations Reliable DNA or RNA tests for the rapid detection of RSV PCR test seroconversion in an IgG assay
  19. 19. Myocoplasma pneumonia Headaches and malasia precede the chest symptoms by 1-5 days Cough may not obvious chest may be scanty
  20. 20.  chest X-ray - one lobe is involved but sometimes may shadowing in both lungs frequently no correlation between the X-ray appearances and the clinical state of the patient.
  21. 21. Investigation Serology : acute phase serumtitre > 1:160 or paired samples taken 2-4 weeks apart showing a 4 fold rise is a good indicator of Mycoplasma pneumoniae infection This test should be considered for children aged five years or older
  22. 22. Management Assessment of oxygenation The best objective measurement of hypoxia is by pulse oximetry which avoids the need for arterial blood gases. It is a good indicator of the severity of pneumonia
  23. 23. Criteria forhospitalization community acquired pneumonia can be treated at home it is crucial to identify indicators of severity in children who may need admission. Failure to recognise the severity of pneumonia may lead to death.
  24. 24. The following indicators can be used as aguide for admission: children aged 3 months and below, whatever the severity of pneumonia. fever ( more than 38.5 ⁰C ), refusal to feed and vomiting fast breathing with or without cyanosis associated systemic manifestation failure of previous antibiotic therapy recurrent pneumonia severe underlying disorder ( i.e. immunodefi ciency )
  25. 25. Antibiotics Bacterial pathogens of children and the recommended antimicrobial agents to be used:Pathogen Antimicrobial agentBeta-lactam susceptibleStreptococcus pneumonia penicillin, cephalosporinsHaemophilus influenzae type b ampicillin, chloramphenicol, cephalosporinsStaphylococcus aureus cloxacillinGroup A Streptococcus penicillin, cephalosporinMycoplasma pneumoniae macrolides , e.g. erythromycin, azithromycinChlamydia pneumoniae macrolides , e.g. erythromycin, azithromycinBordetella pertussis macrolides , e.g. erythromycin, azithromycin
  26. 26. Children with severe pneumonia, the followingantibiotics are recommended:Suggested antimicrobial agents for inpatienttreatment of pneumonia1st line beta-lactam drugs : benzylpenicillin, amoxycillin, ampicillin, amoxycillin-clavulanate2nd line cephalosporins : cefotaxime, cefuroxime, ceftazidime3rd line carbapenem: imipenamOthers aminoglycosides: gentamicin, amikacin
  27. 27. • second line antibiotics need to be considered when : - there are no signs of recovery - patients remain toxic and ill with spiking temperature for 48 - 72 hours• a macrolide antibiotic is used if Mycoplasma or Chlamydia are the causative agents• a child admitied to hospital with severe community acquired pneumonia must receive parenteral antibiotics. As a rule, in severe cases of pneumonia, combination therapy using a second or third generation cephalosporins and macrolide should be given.
  28. 28. Supportive treatment Fluids Oxygen Temperature control Chest physiotherapy
  29. 29. Complications of pneumonia Pleural effusion Empyema Pericarditis Lung abscess Respiratory failure Meningitis Suppurative arthritis Osteomyelitis
  30. 30. Org Strep Staph Mycoplasm RSV HIV(PCP Comparism of common organisms causing a ) pneumonia incom Commonest PaedIv drugs users or population -acq with cental venous catheters Any ageAge 3mth -childhood Noenatal-- >5yrs <3mths infancy high fever,Clinical Broncho in young Fever Headaches, upper respiratory breathlessFeature child Tachypnea Malaise, ness and Lobar/consolidation Cyanosis Chest tract infection, dry cough in older Extremely ill symptoms. Fever,tachyp F,Rusty sputum nea diffuse Haemoptysis bilateral Pleuritic pain alveolar O/E- and interstitial shadowinInv- CXR multi lobar Not Infiltr ate g perihilar consolidati on, correlate In affect- regions cavitation, with clinical ed area spread out pneumatocoel state in a es butterfly patternTx 1st line Iv flucloxacillin Erythromycin, HAART 2nd line (200mg/kg/d) Clarithromycin
  31. 31. The End